Pharmaceutical Technology on MSN1d
AstraZeneca’s Tagrisso gains FDA approval for stage III NSCLC
The FDA has approved AstraZeneca's Tagrisso (osimertinib) to treat adults with unresectable stage III EGFR-mutated NSCLC.
Zacks.com on MSN2d
AZN's Tagrisso Gets FDA Nod for Expanded Use in NSCLC
AstraZeneca AZN announced that the FDA has approved its blockbuster drug, Tagrisso (osimertinib) for expanded use in lung ...
Medscape1d
FDA Okays Osimertinib After CRT in Locally Advanced, Unresectable NSCLC
The US Food and Drug Administration (FDA) has approved osimertinib (Tagrisso, AstraZeneca Pharmaceuticals) for the treatment ...
The American Journal of Managed Care2d
FDA Approves Osimertinib in Stage III NSCLC
The approval means an additional indication for osimertinib (Tagrisso; AstraZeneca) for adult patients who have unresectable ...
Monthly Prescribing Reference2d
Tagrisso Approved for Stage III Unresectable EGFR-Mutated NSCLC
Results showed treatment with osimertinib reduced the risk of disease progression or death by 84% compared with placebo.
MedPage Today3d
FDA Expands Approval of Osimertinib in Lung Cancer
The FDA has approved osimertinib (Tagrisso) for locally advanced, unresectable stage III non-small cell lung cancer (NSCLC) ...
AstraZeneca's Top-Selling Cancer Drug Tagrisso Receives FDA Green Light For Another Lung Cancer Indication
Tagrisso (osimertinib)​ for adult patients with unresectable, Stage III epidermal growth factor receptor-mutated (EGFRm) ...
pharmaphorum2d
AZ gets sought-after lung cancer approval for Tagrisso
AstraZeneca's EGFR inhibitor Tagrisso has been approved by the FDA for a new lung cancer indication that could make it a ...
Business Wire2d
TAGRISSO ® (osimertinib) approved in the US for patients with unresectable, Stage III EGFR-mutated lung cancer
WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca’s TAGRISSO ® (osimertinib) has been approved in the US for the treatment of adult patients with unresectable, Stage III epidermal growth factor ...
Cure Today3d
FDA Approves Tagrisso for Some With Advanced NSCLC
Tagrisso has been approved for some adults with locally advanced, unresectable stage 3 non-small cell lung cancer.
Targeted Oncology4d
Building on the Success of Osimertinib in EGFR-Mutated NSCLC
Suresh S. Ramalingam, MD, FACP, FASCO, discusses the background and next steps of the LAURA study which evaluated osimertinib ...
AstraZeneca: FDA Approves Tagrisso To Treat Unresectable Stage III Lung Cancer
British drug major AstraZeneca PLC (AZN, AZN.L) announced Thursday that its Tagrisso (osimertinib) has been approved in the US for ...